NCT03861793View on ClinicalTrials.gov

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

116

Participants

Timeline

Start Date

February 26, 2019

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2023

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

ALKS 4230

SC injection administered in the back of the arm or the abdomen

BIOLOGICAL

Pembrolizumab

Administered as an intravenous (IV) infusion over 30 minutes

Trial Locations (48)

100

Mural Oncology Investigational Site, Taipei

704

Mural Oncology Investigational Site, Tainan City

6351

Samsung Medical Center, Seoul

10408

National Cancer Center, Goyang

11217

Mural Oncology Investigational Site, Taipei

11259

Mural Oncology Investigational Site, Taipei

13620

Seoul National University Bundang Hospital, Seongnam

14004

Mural Oncology Investigational Site, Córdoba

14263

Mural Oncology Investigational Site, Buffalo

16247

The Catholic University of Korea St. Vincent's Hospital, Suwon

19111

Mural Oncology Investigational Site, Philadelphia

20007

Mural Oncology Investigational Site, Washington D.C.

20817

Mural Oncology Investigational Site, Bethesda

22332

Inha University Hospital, Incheon

28007

Mural Oncology Investigational Site, Madrid

28040

Mural Oncology Investigational Site, Madrid

28041

Mural Oncology Investigational Site, Madrid

28050

Mural Oncology Investigational Site, Madrid

28078

Mural Oncology Investigational Site, Huntersville

28222

Mural Oncology Investigational Site, Madrid

29010

Mural Oncology Investigational Site, Málaga

29425

Mural Oncology Investigational Site, Charleston

30322

Mural Oncology Investigational Site, Atlanta

40447

Mural Oncology Investigational Site, Taichung

45229

Mural Oncology Investigational Site, Cincinnati

46010

Mural Oncology Investigational Site, Valencia

48201

Mural Oncology Investigational Site, Detroit

53226

Mural Oncology Investigational Site, Milwaukee

55101

Mural Oncology Investigational Site, Saint Paul

60612

Mural Oncology Investigational Site, Chicago

77030

Mural Oncology Investigational Site, Houston

83301

Mural Oncology Investigational Site, Kaohsiung City

84119

Mural Oncology Investigational Site, Salt Lake City

90025

Mural Oncology Investigational Site, Los Angeles

90211

Mural Oncology Investigational Site, Los Angeles

07962

Mural Oncology Investigational Site, Morristown

T6G 1Z2

Mural Oncology Investigational Site, Edmonton

L8V 5C2

Mural Oncology Investigational Site, Hamilton

H2X 0C1

Mural Oncology Investigational Sites, Montreal

H3A 3J1

Mural Oncology Investigational Site, Montreal

H3T 1E2

Mural Oncology Investigational Site, Montreal

G1R 2J6

Mural Oncology Investigational Site, Québec

3000 CA

Mural Oncology Investigational Site, Rotterdam

3508 GA

Mural Oncology Investigational Site, Utrecht

03080

Seoul National University Hospital, Seoul

03722

Yonsei University Health System - Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

08916

Mural Oncology Investigational Site, Badalona

Sponsors

Lead Sponsor

Mural Oncology, Inc

All Listed Sponsors

lead

Mural Oncology, Inc

INDUSTRY

NCT03861793 - A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | Biotech Hunter | Biotech Hunter